Brown, D. R. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.J. Infect. Dis.199, 926–935 (2009). Arti...
Although it is clear that the HPV vaccine has the potential to lower the prevalence of HPV 6, 11, 16, and 18 infections and related diseases in the M/FN population living in Manitoba, its impact could be mitigated by the relatively high prevalence of other HPV types....
HPV-associated cervical disease is a worldwide health concern. The recently approved prophylactic vaccine against common HR types of HPV is not a treatment for cervical or any other HPV-associated cancer and is not beneficial to individuals already infected with HPV or immuno- compromised patients....
The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada Article 04 January 2018 Cervical cancer screening among English- and Spanish-speaking Hispanic women in an urban safety net health system, 2015–2020 Article Open access 15 June 2023 Estimating...